ReviewModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2020
Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis.
Review in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Assessment of Risk Factors Correlated with Satellites and In-Transit Metastases in Primary Cutaneous Melanomas.Medicina (Kaunas, Lithuania) · 2026Article
- FluorescenceExperimental and therapeutic medicine · 2025Article
- Inhibiting melanoma tumor growth: the role of oxidative stress-associatedFrontiers in immunology · 2025Article
- Review
- Review
- Diagnosing Cutaneous Melanocytic Tumors in the Molecular Era: Updates and Review of Literature.Dermatopathology (Basel, Switzerland) · 2024Review
- A Narrative Review of Molecular, Immunohistochemical and In-Situ Techniques in Dermatopathology.British journal of biomedical science · 2024Review
- Advances in melanoma: epidemiology, diagnosis, and prognosis.Frontiers in medicine · 2023Review
- Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model.Journal of cutaneous pathology · 2021Article
- A Comparative View on Molecular Alterations and Potential Therapeutic Strategies for Canine Oral Melanoma.Veterinary sciences · 2021Review
- Evolution of the Clinical, Dermoscopic and Pathologic Diagnosis of Melanoma.Dermatology practical & conceptual · 2021Review
- Multimodal Imaging Mass Spectrometry: Next Generation Molecular Mapping in Biology and Medicine.Journal of the American Society for Mass Spectrometry · 2020Review
- Primary cilia: putting a sensor on the underlying melanocytic tumor cell state.Melanoma management · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is the leading cause of death among cutaneous neoplasms. Best outcome relies on early detection and accurate pathologic diagnosis. For the great majority of melanocytic tumors, histopathologic examination can reliably distinguish nevi from melanomas. However, there is a subset of melanocytic tumors that cannot be definitively classified as benign or malignant using histopathological criteria alone. These tumors are usually diagnosed using terms that imply various degrees of uncertainty in regards to their malignant potential and create the possibility for over or undertreatment. For such tumors, additional ancillary tests would be beneficial in adjudicating a more definitive diagnosis. In recent years, DNA-based molecular ancillary tests, specifically comparative genomic hybridization and fluorescence in situ hybridization, have been developed to help guide the diagnosis of ambiguous melanocytic proliferations. This study will present an updated overview of these two major ancillary tests, which are currently being used in clinical practice to assist in the diagnosis of challenging melanocytic neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.